Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.38
+1.7%
$2.30
$1.62
$14.67
$5.64M0.97946,443 shs77,921 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.40
+2.2%
$1.12
$0.51
$5.01
$23.69M1.962.20 million shs140,274 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.41
-0.1%
$3.10
$2.57
$6.88
$21.04M0.639,071 shs3,089 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$1.79
+4.1%
$1.20
$0.51
$1.80
$24.46M1.62257,203 shs149,386 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00%+8.68%+14.42%-52.59%-71.62%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
0.00%+3.70%+12.00%+38.61%+79.46%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+1.49%+7.41%-11.10%-47.62%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%+16.99%+70.49%+58.41%+52.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.0181 of 5 stars
0.02.00.00.00.00.00.0
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.2166 of 5 stars
3.75.00.00.03.80.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.5499 of 5 stars
3.53.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.00900.00% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
3.00
Buy$14.00682.12% Upside

Current Analyst Ratings Breakdown

Latest ENSC, NRSN, NAII, and MIRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.23M2.53N/AN/A($3.10) per share-0.77
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.30 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.17N/AN/A$12.77 per share0.27
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.14) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.26%-9.36%-4.82%N/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$11.28M-$0.54N/AN/AN/AN/A-590.79%6/24/2025 (Estimated)

Latest ENSC, NRSN, NAII, and MIRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/24/2025Q1 2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$0.13N/AN/AN/AN/AN/A
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
4/7/2025Q4 2024
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$0.12-$0.06+$0.06-$0.06N/AN/A
3/28/2025Q4 2024
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.29-$0.15+$0.14-$0.15N/AN/A
3/10/2025Q4 2024
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
3.24
3.24
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
6.11
6.11
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.21
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million1.20 millionNot Optionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.46 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.90 millionNot Optionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1013.67 million9.92 millionNot Optionable

Recent News About These Companies

Top Nasdaq Companies by Market Cap Ranked by Kalkine
NeuroSense regains Nasdaq compliance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.38 +0.04 (+1.71%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$2.43 +0.05 (+1.93%)
As of 06/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.40 +0.03 (+2.19%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$1.38 -0.01 (-1.07%)
As of 06/6/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.40 -0.01 (-0.15%)
As of 06/6/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$1.79 +0.07 (+4.07%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$1.82 +0.02 (+1.40%)
As of 06/6/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.